GBA1 and Parkinson disease: Calnexin levels were significantly elevated in Gaucher disease fibroblasts [median 50% increase (IQR 50–100%), Mann-Whitney U-test P = 0.003] and Parkinson’s disease with GBA mutation fibroblasts [median 32% increase (IQR 12–50%), P = 0.019].